The 4.5 year academic–industrial collaboration
between the
process chemistry group at Lilly and the Stephenson group (Boston
University and University of Michigan) is summarized. From the industrial
perspective, the relationship benefitted Lilly by enabling the development
of visible-light photoredox catalysis processes with an expert partner
as well as the establishment of internal technology platforms to support
such processes. In addition to the funding element, the academic side
benefited from the ability to access pharmaceutically relevant problems
and tap into continuous processing capabilities at Lilly. Another
positive outcome of the collaboration was the inspiration of spinoff
projects, which themselves generated substantial value in the academic
setting. The postdoctoral researchers involved benefitted from the
unique mentorship opportunity provided by the collaboration and access
to resources from both academia and industry. We will analyze the
impact of the collaboration in terms of personal development, publications,
and new technologies that resulted, which we feel were highly beneficial
for both sides of the collaboration.
A simple method for accessing trans‐2,3‐diaryl dihydrobenzofurans is reported. This approach leverages the equilibrium between quinone methide dimers and their persistent radicals. This equilibrium is disrupted by phenols that yield comparatively transient phenoxyl radicals, leading to cross‐coupling between the persistent and transient radicals. The resultant quinone methides with pendant phenols rapidly cyclize to form dihydrobenzofurans (DHBs). This putative biomimetic access to dihydrobenzofurans provides superb functional group tolerance and a unified approach for the synthesis of resveratrol‐based natural products.
A simple method for accessing trans-2,3-diaryl-dihydrobenzofurans is reported. This approach leverages a persistent radical equilibrium between quinone methide dimers and the persistent phenoxyl radicals derived therefrom. This equilibrium is disrupted by phenols that yield transient phenoxyl radicals, leading to cross-coupling between persistent and transient radicals. The resultant quinone methides with pendant phenols rapidly cyclize to dihydrobenzofurans (DHBs). This putatively biomimetic access to dihydrobenzofurans provides superb functional group tolerance and a unified approach for the synthesis of resveratrol-based natural products.
A simple method for accessing trans-2,3-diaryl-dihydrobenzofurans is reported. This approach leverages a persistent radical equilibrium between quinone methide dimers and the persistent phenoxyl radicals derived therefrom. This equilibrium is disrupted by phenols that yield transient phenoxyl radicals, leading to cross-coupling between persistent and transient radicals. The resultant quinone methides with pendant phenols rapidly cyclize to dihydrobenzofurans (DHBs). This putatively biomimetic access to dihydrobenzofurans provides superb functional group tolerance and a unified approach for the synthesis of resveratrol-based natural products.
A simple method for accessing trans‐2,3‐diaryl dihydrobenzofurans is reported. This approach leverages the equilibrium between quinone methide dimers and their persistent radicals. This equilibrium is disrupted by phenols that yield comparatively transient phenoxyl radicals, leading to cross‐coupling between the persistent and transient radicals. The resultant quinone methides with pendant phenols rapidly cyclize to form dihydrobenzofurans (DHBs). This putative biomimetic access to dihydrobenzofurans provides superb functional group tolerance and a unified approach for the synthesis of resveratrol‐based natural products.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.